Danqing Zhu, Keyi Shi, Dongxiao Hu, Wanrun Lin, Xiaofei Zhang, Feng Zhou, Yang Li
{"title":"Clinicopathological and Molecular Characterization of Non-Endometrioid Endometrial Carcinoma.","authors":"Danqing Zhu, Keyi Shi, Dongxiao Hu, Wanrun Lin, Xiaofei Zhang, Feng Zhou, Yang Li","doi":"10.7150/jca.108685","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> Molecular classification has become an essential tool in endometrial carcinoma; however, its application in non-endometrioid carcinoma (NEEC), particularly rare histological subtypes, remains relatively unexplored. This study aims to investigate the potential utility of molecular classification in NEEC. <b>Methods</b>: A retrospective analysis was conducted on 167 NEEC cases diagnosed at the Women's Hospital of Zhejiang University from 2013 to 2020. The cases were categorized into four molecular subtypes: <i>POLE</i> ultra-mutated (<i>POLE</i>mut), mismatch repair-deficient (MMRd), p53-abnormal (p53abn), and no specific molecular profile (NSMP) molecular subgroups<i>.</i> Statistical significance was set at <i>P</i><0.05. <b>Results:</b> Among the cases, 13 (7.8%) patients were classified as <i>POLE</i>mut, 25 (15.0%) as MMRd, 84 (50.3%) as p53abn, and 45 (27.0%) as NSMP. Most <i>POLE</i>mut cases were at early stages (11/13, 84.6% at stages I-II), whereas p53abn cases were predominantly at advanced stages (32/49, 65.3% at stages III-IV). Additionally, p53abn was the most common subtype in serous carcinoma (41/45, 91.1%) and mixed adenocarcinoma (24/57, 42.1%). The 3-year recurrence-free survival (RFS) rates for <i>POLE</i>mut, MMRd, NSMP, and p53abn were 100.0%, 88.0%, 73.3%, and 71.4% , respectively. The 3-year overall survival (OS) rates were 100.0%, 88.0%, 82.2%, and 73.8%, respectively. Univariate analysis revealed significant associations of age ≥60 years (<i>P</i>=0.01), hypertension (<i>P</i>=0.03), FIGO stage (<i>P</i><0.001), lymphovascular space invasion (<i>P</i>=0.01), lymph node metastasis (<i>P</i><0.001), myometrial invasion (<i>P</i><0.001), and postoperative adjuvant therapy (<i>P</i>=0.01) with 3-year RFS. Multivariate analysis identified age ≥60 years (<i>P</i>=0.03), myometrial invasion (<i>P</i>=0.01), and FIGO stage (<i>P</i>=0.046) as independent risk factors for 3-year OS. <b>Conclusion:</b> Molecular classification is crucial for accurately predicting the prognosis of NEEC, enabling more tailored treatment approaches in clinical practice. Furthermore, patient age may have a significant influence on NEEC classification and progression.</p>","PeriodicalId":15183,"journal":{"name":"Journal of Cancer","volume":"16 7","pages":"2312-2320"},"PeriodicalIF":3.3000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12036092/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/jca.108685","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Molecular classification has become an essential tool in endometrial carcinoma; however, its application in non-endometrioid carcinoma (NEEC), particularly rare histological subtypes, remains relatively unexplored. This study aims to investigate the potential utility of molecular classification in NEEC. Methods: A retrospective analysis was conducted on 167 NEEC cases diagnosed at the Women's Hospital of Zhejiang University from 2013 to 2020. The cases were categorized into four molecular subtypes: POLE ultra-mutated (POLEmut), mismatch repair-deficient (MMRd), p53-abnormal (p53abn), and no specific molecular profile (NSMP) molecular subgroups. Statistical significance was set at P<0.05. Results: Among the cases, 13 (7.8%) patients were classified as POLEmut, 25 (15.0%) as MMRd, 84 (50.3%) as p53abn, and 45 (27.0%) as NSMP. Most POLEmut cases were at early stages (11/13, 84.6% at stages I-II), whereas p53abn cases were predominantly at advanced stages (32/49, 65.3% at stages III-IV). Additionally, p53abn was the most common subtype in serous carcinoma (41/45, 91.1%) and mixed adenocarcinoma (24/57, 42.1%). The 3-year recurrence-free survival (RFS) rates for POLEmut, MMRd, NSMP, and p53abn were 100.0%, 88.0%, 73.3%, and 71.4% , respectively. The 3-year overall survival (OS) rates were 100.0%, 88.0%, 82.2%, and 73.8%, respectively. Univariate analysis revealed significant associations of age ≥60 years (P=0.01), hypertension (P=0.03), FIGO stage (P<0.001), lymphovascular space invasion (P=0.01), lymph node metastasis (P<0.001), myometrial invasion (P<0.001), and postoperative adjuvant therapy (P=0.01) with 3-year RFS. Multivariate analysis identified age ≥60 years (P=0.03), myometrial invasion (P=0.01), and FIGO stage (P=0.046) as independent risk factors for 3-year OS. Conclusion: Molecular classification is crucial for accurately predicting the prognosis of NEEC, enabling more tailored treatment approaches in clinical practice. Furthermore, patient age may have a significant influence on NEEC classification and progression.
期刊介绍:
Journal of Cancer is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer. The Journal is supported by an international editorial board consisting of a distinguished team of cancer researchers. Journal of Cancer aims at rapid publication of high quality results in cancer research while maintaining rigorous peer-review process.